Acute intermittent porphyria (AIP) is a rare metabolic disorder that is characterized by partial deficiency of the enzyme hydroxymethylbilane synthase (also known as porphobilinogen deaminase). This enzyme deficiency can result in the accumulation of porphyrin precursors in the body.
MARKET DYNAMICS
The acute intermittent porphyria market is driving due to expanding prevalence of rare diseases, developing interest for better treatment. However, less awareness among people could restrict the market growth in the next few years.
MARKET SCOPE
The "Acute Intermittent Porphyria Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of acute intermittent porphyria market with detailed market segmentation diagnosis, treatment, and end-user. and region. The acute intermittent porphyria market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in acute intermittent porphyria market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The acute intermittent porphyria market is segmented on the basis of diagnosis, treatment, and end-user. In terms of diagnosis, the global acute intermittent porphyria market can be classified into blood test, serum test, urine test, DNA test, and others. Based on treatment, the global acute intermittent porphyria market can be categorized into prophylactic hematin infusions, gonadotropin-releasing hormone analogues, and others. In terms of end-user, the market can be divided into hospitals, clinics, research centers, and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Acute Intermittent Porphyria market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Acute Intermittent Porphyria market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Acute Intermittent Porphyria market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Acute Intermittent Porphyria market in these regions.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Acute Intermittent Porphyria market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Acute Intermittent Porphyria market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Acute Intermittent Porphyria market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Acute Intermittent Porphyria market in these regions.
MARKET PLAYERS
The report covers key developments in the acute intermittent porphyria market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from acute intermittent porphyria market are anticipated to have lucrative growth opportunities in the future with the rising demand for acute intermittent porphyria market in the global market. Below mentioned is the list of few companies engaged in the acute intermittent porphyria market.
The report also includes the profiles of key players in acute intermittent porphyria market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Recordati Rare Diseases Inc.
- Lundbeck Inc.
- Alnylam Pharmaceuticals, Inc.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Acute Intermittent Porphyria Market - By Diagnosis
1.3.2 Acute Intermittent Porphyria Market - By Treatment
1.3.3 Acute Intermittent Porphyria Market - By End-User
1.3.4 Acute Intermittent Porphyria Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ACUTE INTERMITTENT PORPHYRIA MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ACUTE INTERMITTENT PORPHYRIA MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ACUTE INTERMITTENT PORPHYRIA MARKET - GLOBAL MARKET ANALYSIS
6.1. ACUTE INTERMITTENT PORPHYRIA - GLOBAL MARKET OVERVIEW
6.2. ACUTE INTERMITTENT PORPHYRIA - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ACUTE INTERMITTENT PORPHYRIA MARKET - REVENUE AND FORECASTS TO 2028 - DIAGNOSIS
7.1. OVERVIEW
7.2. DIAGNOSIS MARKET FORECASTS AND ANALYSIS
7.3. BLOOD TEST
7.3.1. Overview
7.3.2. Blood Test Market Forecast and Analysis
7.4. SERUM TEST
7.4.1. Overview
7.4.2. Serum Test Market Forecast and Analysis
7.5. URINE TEST
7.5.1. Overview
7.5.2. Urine Test Market Forecast and Analysis
7.6. DNA TEST
7.6.1. Overview
7.6.2. DNA Test Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. ACUTE INTERMITTENT PORPHYRIA MARKET - REVENUE AND FORECASTS TO 2028 - TREATMENT
8.1. OVERVIEW
8.2. TREATMENT MARKET FORECASTS AND ANALYSIS
8.3. PROPHYLACTIC HEMATIN INFUSIONS
8.3.1. Overview
8.3.2. Prophylactic Hematin Infusions Market Forecast and Analysis
8.4. GONADOTROPIN-RELEASING HORMONE ANALOGUES
8.4.1. Overview
8.4.2. Gonadotropin-Releasing Hormone Analogues Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. ACUTE INTERMITTENT PORPHYRIA MARKET - REVENUE AND FORECASTS TO 2028 - END-USER
9.1. OVERVIEW
9.2. END-USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. CLINICS
9.4.1. Overview
9.4.2. Clinics Market Forecast and Analysis
9.5. RESEARCH CENTERS
9.5.1. Overview
9.5.2. Research Centers Market Forecast and Analysis
9.6. OTHERS
9.6.1. Overview
9.6.2. Others Market Forecast and Analysis
10. ACUTE INTERMITTENT PORPHYRIA MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Acute Intermittent Porphyria Market Overview
10.1.2 North America Acute Intermittent Porphyria Market Forecasts and Analysis
10.1.3 North America Acute Intermittent Porphyria Market Forecasts and Analysis - By Diagnosis
10.1.4 North America Acute Intermittent Porphyria Market Forecasts and Analysis - By Treatment
10.1.5 North America Acute Intermittent Porphyria Market Forecasts and Analysis - By End-User
10.1.6 North America Acute Intermittent Porphyria Market Forecasts and Analysis - By Countries
10.1.6.1 United States Acute Intermittent Porphyria Market
10.1.6.1.1 United States Acute Intermittent Porphyria Market by Diagnosis
10.1.6.1.2 United States Acute Intermittent Porphyria Market by Treatment
10.1.6.1.3 United States Acute Intermittent Porphyria Market by End-User
10.1.6.2 Canada Acute Intermittent Porphyria Market
10.1.6.2.1 Canada Acute Intermittent Porphyria Market by Diagnosis
10.1.6.2.2 Canada Acute Intermittent Porphyria Market by Treatment
10.1.6.2.3 Canada Acute Intermittent Porphyria Market by End-User
10.1.6.3 Mexico Acute Intermittent Porphyria Market
10.1.6.3.1 Mexico Acute Intermittent Porphyria Market by Diagnosis
10.1.6.3.2 Mexico Acute Intermittent Porphyria Market by Treatment
10.1.6.3.3 Mexico Acute Intermittent Porphyria Market by End-User
10.2. EUROPE
10.2.1 Europe Acute Intermittent Porphyria Market Overview
10.2.2 Europe Acute Intermittent Porphyria Market Forecasts and Analysis
10.2.3 Europe Acute Intermittent Porphyria Market Forecasts and Analysis - By Diagnosis
10.2.4 Europe Acute Intermittent Porphyria Market Forecasts and Analysis - By Treatment
10.2.5 Europe Acute Intermittent Porphyria Market Forecasts and Analysis - By End-User
10.2.6 Europe Acute Intermittent Porphyria Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Acute Intermittent Porphyria Market
10.2.6.1.1 Germany Acute Intermittent Porphyria Market by Diagnosis
10.2.6.1.2 Germany Acute Intermittent Porphyria Market by Treatment
10.2.6.1.3 Germany Acute Intermittent Porphyria Market by End-User
10.2.6.2 France Acute Intermittent Porphyria Market
10.2.6.2.1 France Acute Intermittent Porphyria Market by Diagnosis
10.2.6.2.2 France Acute Intermittent Porphyria Market by Treatment
10.2.6.2.3 France Acute Intermittent Porphyria Market by End-User
10.2.6.3 Italy Acute Intermittent Porphyria Market
10.2.6.3.1 Italy Acute Intermittent Porphyria Market by Diagnosis
10.2.6.3.2 Italy Acute Intermittent Porphyria Market by Treatment
10.2.6.3.3 Italy Acute Intermittent Porphyria Market by End-User
10.2.6.4 Spain Acute Intermittent Porphyria Market
10.2.6.4.1 Spain Acute Intermittent Porphyria Market by Diagnosis
10.2.6.4.2 Spain Acute Intermittent Porphyria Market by Treatment
10.2.6.4.3 Spain Acute Intermittent Porphyria Market by End-User
10.2.6.5 United Kingdom Acute Intermittent Porphyria Market
10.2.6.5.1 United Kingdom Acute Intermittent Porphyria Market by Diagnosis
10.2.6.5.2 United Kingdom Acute Intermittent Porphyria Market by Treatment
10.2.6.5.3 United Kingdom Acute Intermittent Porphyria Market by End-User
10.2.6.6 Rest of Europe Acute Intermittent Porphyria Market
10.2.6.6.1 Rest of Europe Acute Intermittent Porphyria Market by Diagnosis
10.2.6.6.2 Rest of Europe Acute Intermittent Porphyria Market by Treatment
10.2.6.6.3 Rest of Europe Acute Intermittent Porphyria Market by End-User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Acute Intermittent Porphyria Market Overview
10.3.2 Asia-Pacific Acute Intermittent Porphyria Market Forecasts and Analysis
10.3.3 Asia-Pacific Acute Intermittent Porphyria Market Forecasts and Analysis - By Diagnosis
10.3.4 Asia-Pacific Acute Intermittent Porphyria Market Forecasts and Analysis - By Treatment
10.3.5 Asia-Pacific Acute Intermittent Porphyria Market Forecasts and Analysis - By End-User
10.3.6 Asia-Pacific Acute Intermittent Porphyria Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Acute Intermittent Porphyria Market
10.3.6.1.1 Australia Acute Intermittent Porphyria Market by Diagnosis
10.3.6.1.2 Australia Acute Intermittent Porphyria Market by Treatment
10.3.6.1.3 Australia Acute Intermittent Porphyria Market by End-User
10.3.6.2 China Acute Intermittent Porphyria Market
10.3.6.2.1 China Acute Intermittent Porphyria Market by Diagnosis
10.3.6.2.2 China Acute Intermittent Porphyria Market by Treatment
10.3.6.2.3 China Acute Intermittent Porphyria Market by End-User
10.3.6.3 India Acute Intermittent Porphyria Market
10.3.6.3.1 India Acute Intermittent Porphyria Market by Diagnosis
10.3.6.3.2 India Acute Intermittent Porphyria Market by Treatment
10.3.6.3.3 India Acute Intermittent Porphyria Market by End-User
10.3.6.4 Japan Acute Intermittent Porphyria Market
10.3.6.4.1 Japan Acute Intermittent Porphyria Market by Diagnosis
10.3.6.4.2 Japan Acute Intermittent Porphyria Market by Treatment
10.3.6.4.3 Japan Acute Intermittent Porphyria Market by End-User
10.3.6.5 South Korea Acute Intermittent Porphyria Market
10.3.6.5.1 South Korea Acute Intermittent Porphyria Market by Diagnosis
10.3.6.5.2 South Korea Acute Intermittent Porphyria Market by Treatment
10.3.6.5.3 South Korea Acute Intermittent Porphyria Market by End-User
10.3.6.6 Rest of Asia-Pacific Acute Intermittent Porphyria Market
10.3.6.6.1 Rest of Asia-Pacific Acute Intermittent Porphyria Market by Diagnosis
10.3.6.6.2 Rest of Asia-Pacific Acute Intermittent Porphyria Market by Treatment
10.3.6.6.3 Rest of Asia-Pacific Acute Intermittent Porphyria Market by End-User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Acute Intermittent Porphyria Market Overview
10.4.2 Middle East and Africa Acute Intermittent Porphyria Market Forecasts and Analysis
10.4.3 Middle East and Africa Acute Intermittent Porphyria Market Forecasts and Analysis - By Diagnosis
10.4.4 Middle East and Africa Acute Intermittent Porphyria Market Forecasts and Analysis - By Treatment
10.4.5 Middle East and Africa Acute Intermittent Porphyria Market Forecasts and Analysis - By End-User
10.4.6 Middle East and Africa Acute Intermittent Porphyria Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Acute Intermittent Porphyria Market
10.4.6.1.1 South Africa Acute Intermittent Porphyria Market by Diagnosis
10.4.6.1.2 South Africa Acute Intermittent Porphyria Market by Treatment
10.4.6.1.3 South Africa Acute Intermittent Porphyria Market by End-User
10.4.6.2 Saudi Arabia Acute Intermittent Porphyria Market
10.4.6.2.1 Saudi Arabia Acute Intermittent Porphyria Market by Diagnosis
10.4.6.2.2 Saudi Arabia Acute Intermittent Porphyria Market by Treatment
10.4.6.2.3 Saudi Arabia Acute Intermittent Porphyria Market by End-User
10.4.6.3 U.A.E Acute Intermittent Porphyria Market
10.4.6.3.1 U.A.E Acute Intermittent Porphyria Market by Diagnosis
10.4.6.3.2 U.A.E Acute Intermittent Porphyria Market by Treatment
10.4.6.3.3 U.A.E Acute Intermittent Porphyria Market by End-User
10.4.6.4 Rest of Middle East and Africa Acute Intermittent Porphyria Market
10.4.6.4.1 Rest of Middle East and Africa Acute Intermittent Porphyria Market by Diagnosis
10.4.6.4.2 Rest of Middle East and Africa Acute Intermittent Porphyria Market by Treatment
10.4.6.4.3 Rest of Middle East and Africa Acute Intermittent Porphyria Market by End-User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Acute Intermittent Porphyria Market Overview
10.5.2 South and Central America Acute Intermittent Porphyria Market Forecasts and Analysis
10.5.3 South and Central America Acute Intermittent Porphyria Market Forecasts and Analysis - By Diagnosis
10.5.4 South and Central America Acute Intermittent Porphyria Market Forecasts and Analysis - By Treatment
10.5.5 South and Central America Acute Intermittent Porphyria Market Forecasts and Analysis - By End-User
10.5.6 South and Central America Acute Intermittent Porphyria Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Acute Intermittent Porphyria Market
10.5.6.1.1 Brazil Acute Intermittent Porphyria Market by Diagnosis
10.5.6.1.2 Brazil Acute Intermittent Porphyria Market by Treatment
10.5.6.1.3 Brazil Acute Intermittent Porphyria Market by End-User
10.5.6.2 Argentina Acute Intermittent Porphyria Market
10.5.6.2.1 Argentina Acute Intermittent Porphyria Market by Diagnosis
10.5.6.2.2 Argentina Acute Intermittent Porphyria Market by Treatment
10.5.6.2.3 Argentina Acute Intermittent Porphyria Market by End-User
10.5.6.3 Rest of South and Central America Acute Intermittent Porphyria Market
10.5.6.3.1 Rest of South and Central America Acute Intermittent Porphyria Market by Diagnosis
10.5.6.3.2 Rest of South and Central America Acute Intermittent Porphyria Market by Treatment
10.5.6.3.3 Rest of South and Central America Acute Intermittent Porphyria Market by End-User
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. ACUTE INTERMITTENT PORPHYRIA MARKET, KEY COMPANY PROFILES
13.1. RECORDATI RARE DISEASES INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. LUNDBECK INC.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. ALNYLAM PHARMACEUTICALS, INC.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. Recordati Rare Diseases Inc.
2. Lundbeck Inc.
3. Alnylam Pharmaceuticals, Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For